<code id='1317B11685'></code><style id='1317B11685'></style>
    • <acronym id='1317B11685'></acronym>
      <center id='1317B11685'><center id='1317B11685'><tfoot id='1317B11685'></tfoot></center><abbr id='1317B11685'><dir id='1317B11685'><tfoot id='1317B11685'></tfoot><noframes id='1317B11685'>

    • <optgroup id='1317B11685'><strike id='1317B11685'><sup id='1317B11685'></sup></strike><code id='1317B11685'></code></optgroup>
        1. <b id='1317B11685'><label id='1317B11685'><select id='1317B11685'><dt id='1317B11685'><span id='1317B11685'></span></dt></select></label></b><u id='1317B11685'></u>
          <i id='1317B11685'><strike id='1317B11685'><tt id='1317B11685'><pre id='1317B11685'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:95
          Cynthia Fisher on stage at the 2023 STAT Summit.
          Cynthia Fisher, founder and chairman, PatientRightsAdvocate.org STAT

          BOSTON — For all those who think hospital price transparency will not save money, Cynthia Fisher has a message: it’s already doing so.

          Fisher, who spoke Wednesday at the annual STAT Summit in Boston, is the successful entrepreneur and founder of PatientRightsAdvocate.org who has been leading an unorthodox campaign to get hospitals to disclose prices.

          advertisement

          The campaign has made progress. Republicans on three House committees introduced a bill to make hospitals disclose prices up front, though then-House Speaker Kevin McCarthy (R-Calif.) pulled the bill shortly before it was supposed to receive a vote on the House floor.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Boston Scientific acquires urology company Axonics for $3.7 billion
          Boston Scientific acquires urology company Axonics for $3.7 billion

          BostonScientificisgrowingitsurologyportfoliowiththeAxonicsacquisition.StevenSenne/APBostonScientific

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

          SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletter